Revenue
2020
2021
2022
Elicio Therapeutics, Inc. (ELTX)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.3M | $27.5M | $193,000 |
| Research & development | $24.9M | $33.7M | $23.8M | $18.1M | $48.7M | $39.0M |
| Operating income | −$37.7M | −$45.0M | −$35.7M | −$23.7M | −$39.3M | −$55.3M |
| Net income | −$39.6M | −$51.9M | −$35.2M | −$28.2M | −$54.6M | −$80.1M |
| Basic EPSper diluted share | -$2.58 | -$4.25 | -$6.96 | -$89.27 | -$1.93 | -$5.43 |
| Diluted EPSper diluted share | -$2.58 | -$4.25 | -$6.96 | -$89.27 | -$1.93 | -$5.43 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 12, 2024Form 4 | Chudnovsky Yekaterina +1Director,TenPercentOwner | BuyConvertible Note (convertible into Common Stock) · derivative · indirect | 3.44M | $5.81 | $20.00M | 3.44M |
| Jun 28, 2024Form 4/A | Venkatesan JayDirector | BuyPre-Funded Warrants · derivative | 50.0K | $4.99 | $249.5K | 50.0K |
| Jun 28, 2024Form 4/A | Venkatesan JayDirector | BuyCommon Warrants · derivative | 50.0K | $0.00 | $0.00 | 50.0K |
| Jun 28, 2024Form 4 | Venkatesan JayDirector | BuyPre-Funded Warrants · derivative · indirect | 50.0K | $4.99 | $249.5K | 50.0K |
| Jun 28, 2024Form 4 | Venkatesan JayDirector | BuyCommon Warrants · derivative · indirect | 50.0K | $0.00 | $0.00 | 50.0K |